{
    "Trade/Device Name(s)": [
        "Sentinel Ammonia Ultra",
        "Ammonia Ultra",
        "Ammonia Control",
        "Ammonia Controls"
    ],
    "Submitter Information": "Sentinel CH Srl",
    "510(k) Number": "K051114",
    "Predicate Device Reference 510(k) Number(s)": [
        "K974620",
        "K913346"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JIF",
        "JJX"
    ],
    "Summary Letter Date": "November 25, 2005",
    "Summary Letter Received Date": "November 8, 2005",
    "Submission Date": "September 26, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.1065"
    ],
    "Regulation Name(s)": [
        "Ammonia test system",
        "Single (Specified) Analyte Controls (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Ammonia (NH3)"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Abbott ARCHITECT c8000 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic method",
        "NADH oxidation detection"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Calibrator",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Sentinel Ammonia Ultra enzymatic diagnostic assay and controls for quantitative determination of ammonia in human plasma",
    "Indications for Use Summary": "Intended for the in vitro quantitative determination of ammonia (NH3) in human plasma and as controls to monitor the assay, used in diagnosing and treating severe liver disorders such as cirrhosis, hepatitis, and Reye's syndrome",
    "fda_folder": "Clinical Chemistry"
}